Published in final edited form as:

Bioorg Med Chem Lett. 2015 December 1; 25(23): 5609–5612. doi:10.1016/j.bmcl.2015.10.039.

Ethynylphenyl carbonates and carbamates as dual-action acetylcholinesterase inhibitors and anti-inflammatory agents

Jaya Saxena^a, David Meloni^{a,b}, Mou-Tuan Huang^c, Diane E. Heck^d, Jeffrey D. Laskin^e, Ned D. Heindel^a, and Sherri C. Young^{a,f,*}

^aDepartment of Chemistry, Lehigh University, Bethlehem, PA 18015

^bIncyte Corporation, Wilmington, DE 19803

^cDepartment of Chemical Biology, Rutgers University, Piscataway, NJ 08854

^dDepartment of Environmental Health Science, New York Medical College, Valhalla, NY 10595

^eDepartment of Environmental and Occupational Medicine, Rutgers University, Piscataway, NJ 08854

^fDepartment of Chemistry, Muhlenberg College, Allentown, PA 18104

Abstract

Novel ethynylphenyl carbonates and carbamates containing carbon- and silicon-based choline mimics were synthesized from their respective phenol and aniline precursors and screened for anticholinesterase and anti-inflammatory activities. All molecules were micromolar inhibitors of acetylcholinesterase (AChE), with IC₅₀s of 28–86 μM; the carbamates were two-fold more potent than the carbonates. Two of the most potent AChE inhibitors suppressed 12-*O* tetradecanoylphorbol-13-acetate (TPA)-induced inflammation by 40 %. Furthermore, these molecules have physicochemical properties in the range of other CNS drugs. These molecules have the potential to treat inflammation; they could also dually target Alzheimer's disease through restoration of cholinergic balance and inflammation suppression.

Graphical abstract

*Corresponding author. Tel.: +1-484-664-3271; fax: +1-484-664-4113; young@muhlenberg.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary data

Compound characterization (NMR, melting point range, elemental analysis) and details on the clog P and PSA calculations as well as protocols for the synthesis, Ellman assay, reversibility study, and MEIM can be found in the online version of this article.

Keywords

Alzheimer's disease; Acetylcholinesterase inhibitors; Anti-inflammatory drugs; Carbonates; Carbamates

The excessive release of proinflammatory cytokines contributes to a multitude of disorders such as multiple sclerosis,^{1–3} diabetes,⁴ rheumatoid arthritis,⁵ Alzheimer's disease (AD),^{6,7} and Parkinson's disease.^{8,9} While acetylcholinesterase inhibitors (AChEIs) have been extensively explored for the treatment of glaucoma,^{10–12} myasthenia gravis,¹³ Lewy body dementia,^{14,15} and AD,^{16–18} there has been an emerging interest in AChEIs for the treatment of inflammatory disorders. Tracey's work supports a physiological link between inflammation and cholinergic imbalance termed the cholinergic anti-inflammatory pathway.¹⁹ This pathway is mediated by the $\alpha 7$ subunit of the nicotinic acetylcholine (ACh) receptor ($\alpha 7$ -nAChR) and involves regulation of systemic cytokine release by the vagus nerve. ACh has been shown to decrease both central and peripheral release of proinflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-6 (IL-6).²⁰ Potentiation of ACh via inhibition of AChE results in inflammation suppression in models of sepsis, obesity, and endotoxemia. For example, intraperitoneal administration of the AChEIs physostigmine and neostigmine improved survival time in a murine model of sepsis.²¹ Galantamine, an AChEI on the market for AD treatment, also suppresses the release of TNF and IL-6 in a model of endotoxemia²² and alleviates obesity-associated inflammation.²³ Snorrason has shown that ointments of AChEIs such as galantamine or donepezil are useful in alleviating skin inflammations.²⁴ Finally, locally applied neostigmine suppressed inflammation in an inflamed mouse knee model, and topical AChEIs have shown promise in the treatment of hyperhidrosis.^{25–27} Clearly, inhibition of AChE is a promising approach to treating inflammatory disorders. Furthermore, considering the well-documented role of both inflammation^{6,7} and cholinergic dysfunction^{16–18} in AD, anti-inflammatory AChEIs such as those presented herein represent a promising class of dual-action AD therapeutics.

In earlier work directed at the development of potential pesticides, we reported the synthesis and development of a mechanism-based, active-site directed, highly specific AChEI, choline *p*-chloromethylphenyl carbonate iodide (**1**, Figure 1).^{28,29} This candidate was modeled after Bechet's classic mechanism-based albeit rather nonspecific chloromethyldihydrocoumarin (**2**, Figure 1) which inhibited a rather broad set of proteases and esterases. Bechet proposed an electrophilic quinone methide metabolite as the lethal transient which captured the active site nucleophile, presumably serine.^{30,31} The anticholinesterase activity of **1** was assessed, and it performed as a classic mechanism-based inhibitor with irreversible, time-dependent, pseudo first-order enzyme inactivation. Additional reversibility and kinetic studies indicated that the quinone methide electrophile was formed on, and remained in, the active site of the enzyme.^{28,29} Considering the structural and functional similarities between **1** and **2**, it was proposed that the AChE inactivation mechanism by **1** involves a quinone methide intermediate.²⁸ Unfortunately, **1** proved ineffective when screened against fully-developed adult insects, and it was only modestly effective against immature larvae. Furthermore, in control experiments, **1** was unable to cross biological membranes and proved unstable both

in solution and in the solid state, an occurrence traced to its chloromethyl moiety.^{28,29} Despite the limitations of this molecule as a pesticide, it has served as a structural platform for the synthesis and optimization of selective and potent AChEIs by our group.^{32–34}

It is well known in other mechanism-based inhibitors that a terminal unsubstituted ethynyl group on an aromatic ring or on an sp^2 carbon can act as an electrophilic surrogate for a halomethyl. For example, ynenol furyl lactones (**3**, Figure 1) serve as irreversible inhibitors of human leukocyte elastase apparently through transient formation of an electrophilic allenone.³⁵ Considering the documented similarities in reactivity between conjugated ethynyls and halomethyls, we chose to design a new class of ethynylphenyls (Figure 2).

Uncharged isosteres of choline have moderate affinities for AChE, with inhibition constants (K_i) of 7.5 mM and 3.3 mM reported for 3,3-dimethyl-1-butanol and 2-(trimethylsilyl)ethanol, respectively.³⁶ As such, many of the molecules designed by our group, including the molecules presented herein (Figure 2), contain one of these moieties to provide cholinesterase recognition.^{32–34} Substitution of the nitrogen-based choline analog with a carbon- or silicon-based analog may also address the inherent instability and poor membrane permeability of carbonate **1**, while maintaining potent anticholinesterase activity. Furthermore, we decided to replace the *p*-chloromethyl moiety of **1** with an ethynyl group (*vide infra*) because the chloromethyl proved to be a source of instability in other studies.^{28,29}

Presented herein is the design and synthesis of a series of ethynylphenyl carbonates and carbamates linked to lipophilic ACh mimics. Not only do these molecules have the potential to target inflammation, they may also dually target AD through AChE inhibition and inflammation suppression, likely through the cholinergic anti-inflammatory pathway.

A series of ortho- and para-substituted ethynylphenyl carbonates (4–7) and carbamates (8–11) was synthesized from commercially available phenol and aniline precursors (see Supporting Information). The carbonates were isolated via a three-step process, with yields ranging from 9–57 %. The carbamates were synthesized in a single step, resulting in 37–65 % yields. The identities of these novel molecules were confirmed by nuclear magnetic resonance (NMR) spectroscopy and elemental analysis.

When screened in an Ellman assay,³⁷ all compounds inhibited AChE in the micromolar range, with IC_{50} s ranging from 28–86 μ M (Table 1). Out of the series, carbamate **8** was the most potent inhibitor and represents a promising lead for further study. The carbamates proved to be approximately two times more potent AChEIs than the carbonates. The mode of AChE binding of many known carbamate AChEIs (*e.g.*, rivastigmine, physostigmine) involves carbamoylation of the active site serine residue followed by restoration of the active enzyme.³⁸ A critical hydrogen bonding interaction between the nitrogen atom of the carbamate and the histidine residue of the catalytic triad could therefore be responsible for the enhanced potency of the carbamates relative to the carbonates.³⁸ When all other structural elements are conserved, changing the choline mimic from a 3,3-dimethylbutyl to a 2-trimethylsilylethyl moiety does not have a significant impact on AChE inhibition. It is interesting to note that the para-substituted ethynyls were slightly more potent than the

ortho-ethynyls in the carbonate series, perhaps due to steric constraints in the active site gorge of the enzyme.³⁹

Following incubation of AChE with each inhibitor and subsequent gel filtration, 80–100 % of enzyme activity was recovered (Table 1). Interestingly, a higher percentage of enzyme activity was recovered following incubation of AChE with the carbamates (85–100 %) compared to the carbonates (60–83 %), with the exception of carbamate **11**. This difference may be because the more hydrophobic carbonates lead to formation of an acylated enzyme complex which is slower to reactivate than the corresponding carbamylated enzyme complex.⁴⁰ Slow reactivation of other lipophilic acyl complexes of various esterases has been reported previously.^{40–42}

Although it was predicted that these molecules would exhibit suicide-type inhibition similar to that of chloromethyl carbonate **1**, all molecules in this series exhibited either reversible or pseudoirreversible AChE inhibition (Table 1).⁴³ It is important to note that the compound after which this class of molecules was modeled, carbonate **1**, exhibited irreversible, time-dependent, suicide-like AChE inhibition.^{28,29} The irreversible modification of AChE, for example by organophosphates, results in a build-up of ACh at neuromuscular junctions and can lead to adverse effects such as headache, nausea, seizures, paralysis, and death.^{44,45} As such, reversible (or pseudoirreversible) enzyme-inhibitor interactions are desired when exploring therapeutic AChEIs; several reversible (*e.g.*, galantamine) and pseudoirreversible (*e.g.*, rivastigmine) carbamate AChEIs have already been explored for the treatment of AD.^{46,47} Because of the non-permanent nature of the action of these molecules, they could be safely used to treat cholinergic and inflammatory disorders.

A mouse ear inflammation model (MEIM)⁴⁸ using 12-*O*-tetradecanoylphorbol-13-acetate (TPA), a phorbol ester, as the proinflammatory agent was used to investigate the anti-inflammatory properties of the ethynylphenyl carbonates and carbamates (see Supporting Information). The results shown in Table 1 are reported as % suppression of TPA-induced edema. Carbamates **8** and **11**, two of the most potent AChEIs of this series, exhibited statistically significant inflammation suppression in the MEIM, suggesting that this inflammation suppression may be occurring through the cholinergic anti-inflammatory pathway.^{19–23} Since inflammation involves a host of mediators, a direct correlation between AChE inhibition and inflammation suppression is typically not observed. Past work in our group on non-steroidal anti-inflammatory drug (NSAID)-AChEI conjugates suggests that topical anti-inflammatory activities depend upon drug stabilities, lipophilicities, and AChE inhibitory potencies.³³ Carbonates **4** and **5** did not exhibit significant inflammation suppression, either because of their less potent AChE inhibition or because of their lower stabilities compared to the carbamates (or both).⁴⁰

In addition to being anti-inflammatory drug leads, these molecules could serve as dual-action AD drugs. When designing CNS drugs, it is important to consider properties such as molecular weight, water solubility, lipophilicity, and membrane permeability. Drugs which penetrate the blood-brain barrier (BBB) via passive diffusion typically have molecular weights lower than 450 Da, polar surface area (PSA) values lower than 60–90 Å², and calculated octanol-water partition coefficient (cLogP) values of ~3.4.⁴⁹ Table 1 lists cLogP

and PSA values for the ethynylphenyl carbonates and carbamates. Ethynylphenyl carbonates **4** and **5** have cLogP values of 4.41 and are more lipophilic than carbamates **8** and **9**, which have cLogP values of 3.73. PSA values for the entire compound series range from 24.1–29.5 Å². The PSA and cLogP values of these molecules are in the range of other known CNS drugs.^{49,50} In addition, the molecular weights of these ethynyl carbonates and carbamates range from 246 to 262 Da, which is well below the cutoff for BBB-penetrable molecules. Finally, they contain a small number of hydrogen bond donors and acceptors, another commonality among CNS drugs.⁴⁹ Together, these properties suggest that these molecules will have suitable BBB penetrability. Additional calculations and *in vitro* studies are necessary to further investigate the membrane permeabilities and other physicochemical properties of these carbonates and carbamates.

In this study, novel ethynylphenyl carbonates and carbamates were generated and identified as potent inhibitors of AChE. In addition, two of the carbamates, **8** and **11**, exhibited moderate suppression of TPA-induced inflammation. This series of compounds represents a promising platform for the structural optimization of AChEIs for the treatment of both cholinergic and inflammatory disorders, including AD. Future investigations will focus on the stabilities and toxicities of these molecules, as well as their specific mode of binding to AChE.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was funded in part by the National Institutes of Health CounterACT Program through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (award #U54AR055073). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the federal government. Testing methods employed herein are described in detail in the doctoral dissertation (Lehigh University, 2012) of Sherri C. Young.

References

1. Rodgers JM, Miller SD. Yale J Biol Med. 2012; 85:447–468. [PubMed: 23239947]
2. Murta V, Ferrari CC. Mol Cell Neurosci. 2013; 53:6–13. [PubMed: 22771835]
3. Centonze D, Muzio L, Rossi S, Furlan R, Bernardi G, Martino G. Cell Death Differ. 2010; 17:1083–1091. [PubMed: 19927157]
4. Donath MY. Nat Rev Drug Discov. 2014; 13:465–476. [PubMed: 24854413]
5. Shrivastava AK, Pandey A. J Physiol Biochem. 2013; 69:335–347. [PubMed: 23385669]
6. Holmes C. Neuropathol Appl Neurobiol. 2013; 39:51–68. [PubMed: 23046210]
7. Lee Y-J, Han SB, Nam S-Y, Oh K-W, Hong JT. Arch Pharm Res. 2010; 33:1539–1556. [PubMed: 21052932]
8. Collins LM, Toulouse A, Connor TJ, Nolan YM. Neuropharmacology. 2012; 62:2154–2168. [PubMed: 22361232]
9. Wüllner U, Klockgether T. J Neurol. 2003; 250(Suppl 1):I35–38. [PubMed: 12761634]
10. Almasieh M, MacIntyre JN, Pouliot M, Casanova C, Vaucher E, Kelly MEM, Di Polo A. Invest Ophthalmol Vis Sci. 2013; 54:3171–3183. [PubMed: 23599333]
11. Almasieh M, Zhou Y, Kelly ME, Casanova C, Di Polo A. Cell Death Dis. 2010; 1:e27. [PubMed: 21364635]

12. Goldblum D, Garweg JG, Böhnke M. *J Ocul Pharmacol Ther.* 2000; 16:29–35. [PubMed: 10673128]
13. Mehndiratta MM, Pandey S, Kuntzer T. *Cochrane Database Syst Rev.* 2011:CD006986. [PubMed: 21328290]
14. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. *Lancet.* 2000; 356:2031–2036. [PubMed: 11145488]
15. Grace J, Daniel S, Stevens T, Shankar KK, Walker Z, Byrne EJ, Butler S, Wilkinson D, Woolford J, Waite J, McKeith IG. *Int Psychogeriatr.* 2001; 13:199–205. [PubMed: 11495394]
16. Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C, Tumiatti V. *Curr Top Med Chem.* 2013; 13:1771–1786. [PubMed: 23931443]
17. Doody RS, Cummings JL, Farlow MR. *Curr Alzheimer Res.* 2012; 9:773–781. [PubMed: 22175653]
18. Marco L, do Carmo Carreiras M. *Recent Patents CNS Drug Discov.* 2006; 1:105–111.
19. Tracey KJ. *Nature.* 2002; 420:853–859. [PubMed: 12490958]
20. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ. *Nature.* 2000; 405:458–462. [PubMed: 10839541]
21. Hofer S, Eisenbach C, Lukic IK, Schneider L, Bode K, Brueckmann M, Mautner S, Wente MN, Encke J, Werner J, Dalpke AH, Stremmel W, Nawroth PP, Martin E, Krammer PH, Bierhaus A, Weigand MA. *Crit Care Med.* 2008; 36:404–408. [PubMed: 18091537]
22. Pavlov VA, Parrish WR, Rosas-Ballina M, Ochani M, Puerta M, Ochani K, Chavan S, Al-Abed Y, Tracey KJ. *Brain Behav Immun.* 2009; 23:41–45. [PubMed: 18639629]
23. Satapathy SK, Ochani M, Dancho M, Hudson LK, Rosas-Ballina M, Valdes-Ferrer SI, Olofsson PS, Harris YT, Roth J, Chavan S, Tracey KJ, Pavlov VA. *Mol Med Camb Mass.* 2011; 17:599–606. [PubMed: 21738953]
24. Snorrason, E. EU Patent EP2008660. 2008. p. A1
25. Sawynok J. *Pharmacol Rev.* 2003; 55:1–20. [PubMed: 12615951]
26. Grimalt R, Domínguez Tordera P, Callejas MA. *J Cosmet Dermatol.* 2006; 5:294–296. [PubMed: 17716247]
27. Mahendiran S, Burkhart CN, Burkhart CG. *Open Dermatol J.* 2009; 3:195–197.
28. Brenner, NJ.; Heindel, ND.; Levy, MR.; Balasubramanian, V.; Turizo, M.; Burns, HD. Arylcholine Carbonates and Aryl 3,3-Dimethyl-1-butyl Carbonates as Inhibitors and Inactivators of Acetylcholinesterase. In: Baker, DR.; Fenyves, JG.; Moberg, WK., editors. *Synthesis and Chemistry of Agrochemicals II. Vol. 1.* American Chemical Society; Washington, D.C: 1991. p. 469-477.
29. Heindel, ND.; Turizo, M.; Burns, HD.; Balasubramanian, V. US Patent. US5082964 A. 1992.
30. Béchet J-J, Dupaix A, Blagoeva I. *Biochimie.* 1977; 59:231–239. [PubMed: 889929]
31. Béchet J-J, Dupaix A, Roucous C, Bonamy A-M. *Biochimie.* 1977; 59:241–246. [PubMed: 889930]
32. Young S, Fabio K, Guillon C, Mohanta P, Halton TA, Heck DE, Flowers RA, Laskin JD, Heindel ND. *Bioorg Med Chem Lett.* 2010; 20:2987–2990. [PubMed: 20347302]
33. Young SC, Fabio KM, Huang M-T, Saxena J, Harman MP, Guillon CD, Vetrano AM, Heck DE, Flowers RA, Heindel ND, Laskin JD. *J Appl Toxicol.* 2012; 32:135–141. [PubMed: 21319177]
34. Laskin, J.; Heck, D.; Huang, MT.; Fabio, K.; Lacey, CJ.; Young, S.; Mohanta, P.; Guillon, C.; Heindel, N. US Patent. US20120010168 A1. 2012.
35. Copp LJ, Krantz A, Spencer RW. *Biochemistry.* 1987; 26:169–178. [PubMed: 3548814]
36. Cohen SG, Chishti SB, Elkind JL, Reese H, Cohen JB. *J Med Chem.* 1985; 28:1309–1313. [PubMed: 4032433]
37. Ellman GL, Courtney KD, Andres V, Feather-Stone RM. *Biochem Pharmacol.* 1961; 7:88–95. [PubMed: 13726518]
38. Bartolucci C, Siotto M, Ghidini E, Amari G, Bolzoni PT, Racchi M, Villetti G, Delcanale M, Lamba D. *J Med Chem.* 2006; 49:5051–5058. [PubMed: 16913695]

39. Shen T, Tai K, Henchman RH, McCammon JA. *Acc Chem Res.* 2002; 35:332–340. [PubMed: 12069617]
40. Huang TL, Székács A, Uematsu T, Kuwano E, Parkinson A, Hammock BD. *Pharm Res.* 1993; 10:639–648. [PubMed: 8321828]
41. Stoops JK, Horgan DJ, Runnegar MTC, De Jersey J, Webb EC, Zerner B. *Biochemistry.* 1969; 8:2026–2033. [PubMed: 5815945]
42. Jencks WP, Greenzaid P. *Biochemistry.* 1971; 10:1210–1222. [PubMed: 5553326]
43. Darvesh S, Darvesh KV, McDonald RS, Mataija D, Walsh R, Mothana S, Lockridge O, Martin E. *J Med Chem.* 2008; 51:4200–4212. [PubMed: 18570368]
44. Brown MA, Brix KA. *J Appl Toxicol.* 1998; 18:393–408. [PubMed: 9840747]
45. Gunderson CH, Lehmann CR, Sidell FR, Jabbari B. *Neurology.* 1992; 42:946–950. [PubMed: 1315942]
46. Weinstock M, Razin M, Chorev M, Enz A. *J Neural Transm Suppl.* 1994; 43:219–225. [PubMed: 7884403]
47. Giacobini, E. *Cholinesterases and cholinesterase inhibitors.* Martin Dunitz; Blackwell Science; London; Malden, MA: 2000.
48. Casillas RP, Kiser RC, Truxall JA, Singer AW, Shumaker SM, Niemuth NA, Ricketts KM, Mitcheltree LW, Castrejon LR, Blank JA. *J Appl Toxicol.* 2000; 20(Suppl 1):S145–151. [PubMed: 11428628]
49. Pajouhesh H, Lenz GR. *NeuroRX.* 2005; 2:541–553. [PubMed: 16489364]
50. Begley DJ. *Pharmacol Ther.* 2004; 104:29–45. [PubMed: 15500907]

Figure 1. Choline *p*-chloromethylphenyl carbonate iodide (**1**),^{28,29} Bechet's chloromethyldihydrocoumarin antiprotease (**2**),^{30,31} and a generic ynenol furyl lactone (**3**).³⁵

4 , X = C, Y = O; ortho-	8 , X = C, Y = NH; ortho-
5 , X = C, Y = O; para-	9 , X = C, Y = NH; para-
6 , X = Si, Y = O; ortho-	10 , X = Si, Y = NH; ortho-
7 , X = Si, Y = O; para-	11 , X = Si, Y = NH; para-

Figure 2.
Ethynylphenyl carbonates (**4–7**) and carbamates (**8–11**).

IC₅₀ values, percent recoveries of AChE activities, percent reductions of TPA-induced edema, cLogP, and PSA values for ethynylphenyl carbonates and carbamates

Table 1

#	IC ₅₀ (μM) ^a	% AChE Recovery	% Red. (TPA) ^b	cLogP ^e	PSA (Å ²) ^h
<i>Ethynylphenyl carbonates</i>					
4	86 ± 1	83 ± 8	18	4.41	24.1
5	59 ± 2	83 ± 5	22	4.41	25.1
6	80 ± 3	78 ± 4	nd	— ^f	24.2
7	62 ± 2	60 ± 11	nd	— ^f	25.2
<i>Ethynylphenyl carbamates</i>					
8	28.4 ± 9	100 ± 9	39 ^c	3.73	27.5
9	34.3 ± 1	95 ± 3	nd	3.73	29.4
10	38.1 ± 1	96 ± 5	irritant	— ^f	27.6
11	34.4 ± 1	85 ± 5	40 ^d	— ^f	29.5
Tacrine	0.058 ± 0.005	95	nd	2.91 ^g	28.4 ^g

^a IC₅₀ values represent mean ± S.D. Individual experiment is performed at least in duplicate; source of AChE is electric eel (*Electrophorus electricus*); enzyme was incubated for 30 min with 52 μM inhibitor at 25 °C.

^b nd: not determined.

^c Value differs from positive control (TPA only) based on one-way ANOVA, with P < 0.05.

^d Value differs from positive control (TPA only) based on one-way ANOVA, with P < 0.10.

^e cLogP values calculated using ChemBioDraw Ultra 14.0.

^f cLogP values could not be calculated.

^g Calculations performed on free base.

^h PSA values calculated using Spartan '14 V1.1.4.